Is Alto Neuroscience, Stock a Good Investment?
Alto Neuroscience, Investment Advice | ANRO |
- Examine Alto Neuroscience,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Alto Neuroscience,'s leadership team and their track record. Good management can help Alto Neuroscience, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Alto Neuroscience,'s business and its evolving consumer preferences.
- Compare Alto Neuroscience,'s performance and market position to its competitors. Analyze how Alto Neuroscience, is positioned in terms of product offerings, innovation, and market share.
- Check if Alto Neuroscience, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Alto Neuroscience,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Alto Neuroscience, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Alto Neuroscience, is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Alto Neuroscience, Stock
Researching Alto Neuroscience,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 89.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alto Neuroscience, recorded a loss per share of 2.5. The entity had not issued any dividends in recent years.
To determine if Alto Neuroscience, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alto Neuroscience,'s research are outlined below:
| Alto Neuroscience, generated a negative expected return over the last 90 days | |
| Alto Neuroscience, has high historical volatility and very poor performance | |
| Net Loss for the year was (61.43 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alto Neuroscience, generates negative cash flow from operations | |
| Alto Neuroscience, has a frail financial position based on the latest SEC disclosures | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights |
Alto Neuroscience, Quarterly Cash And Short Term Investments |
|
Earnings surprises can significantly impact Alto Neuroscience,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Alto Neuroscience,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-14 | 2024-06-30 | -0.67 | -0.6 | 0.07 | 10 | ||
2024-12-31 | 2024-12-31 | -0.65 | -0.52 | 0.13 | 20 | ||
2024-05-14 | 2024-03-31 | -0.46 | -0.76 | -0.3 | 65 | ||
2024-03-21 | 2023-12-31 | -1.67 | -7.77 | -6.1 | 365 |
Alto Neuroscience, Target Price Consensus
Alto target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Alto Neuroscience,'s target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Alto analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Alto stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Alto Neuroscience,, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAlto Neuroscience, Target Price Projection
Alto Neuroscience,'s current and average target prices are 2.65 and 12.72, respectively. The current price of Alto Neuroscience, is the price at which Alto Neuroscience, is currently trading. On the other hand, Alto Neuroscience,'s target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Alto Neuroscience, Market Quote on 24th of March 2025
Target Price
Analyst Consensus On Alto Neuroscience, Target Price
Alto Neuroscience, Analyst Ratings
Alto Neuroscience,'s analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Alto Neuroscience, stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Alto Neuroscience,'s financials, market performance, and future outlook by experienced professionals. Alto Neuroscience,'s historical ratings below, therefore, can serve as a valuable tool for investors.Alto Neuroscience,'s market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 71.47 M.Market Cap |
|
Alto Neuroscience,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.35) | (0.36) | |
| Return On Equity | (0.41) | (0.39) |
Determining Alto Neuroscience,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Alto Neuroscience, is a good buy. For example, gross profit margin measures Alto Neuroscience,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alto Neuroscience,'s profitability and make more informed investment decisions.
Basic technical analysis of Alto Stock
As of the 24th of March, Alto Neuroscience, shows the Mean Deviation of 4.05, standard deviation of 5.11, and Risk Adjusted Performance of (0.07). Alto Neuroscience, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Alto Neuroscience,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alto Neuroscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alto Neuroscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alto Neuroscience, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Etkin Amit over a month ago Acquisition by Etkin Amit of 215000 shares of Alto Neuroscience, at 4.2 subject to Rule 16b-3 | ||
Cox Christopher Nixon over two months ago Acquisition by Cox Christopher Nixon of 25236 shares of Alto Neuroscience, at 4.38 subject to Rule 16b-3 | ||
Savitz Adam over six months ago Acquisition by Savitz Adam of 10681 shares of Alto Neuroscience, at 12.53 subject to Rule 16b-3 | ||
Savitz Adam over six months ago Acquisition by Savitz Adam of 2931 shares of Alto Neuroscience, at 13.22 subject to Rule 16b-3 | ||
Alpha Wave Global Lp over a year ago Conversion by Alpha Wave Global Lp of 1962995 shares of ANRO | ||
Chen Po Yu Jeff over a year ago Conversion by Chen Po Yu Jeff of 259 shares of ANRO | ||
Chen Po Yu Jeff over a year ago Acquisition by Chen Po Yu Jeff of 30574 shares of ANRO subject to Rule 16b-3 | ||
Alkeon Capital Management Llc over a year ago ANRO exotic insider transaction detected |
Understand Alto Neuroscience,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Alto Neuroscience,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.26) | |||
| Mean Deviation | 4.05 | |||
| Coefficient Of Variation | (1,191) | |||
| Standard Deviation | 5.11 | |||
| Variance | 26.16 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.05) | |||
| Treynor Ratio | (1.27) | |||
| Maximum Drawdown | 26.99 | |||
| Value At Risk | (8.14) | |||
| Potential Upside | 8.07 | |||
| Skewness | 0.6697 | |||
| Kurtosis | 1.04 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (1.26) | |||
| Mean Deviation | 4.05 | |||
| Coefficient Of Variation | (1,191) | |||
| Standard Deviation | 5.11 | |||
| Variance | 26.16 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.05) | |||
| Treynor Ratio | (1.27) | |||
| Maximum Drawdown | 26.99 | |||
| Value At Risk | (8.14) | |||
| Potential Upside | 8.07 | |||
| Skewness | 0.6697 | |||
| Kurtosis | 1.04 |
Consider Alto Neuroscience,'s intraday indicators
Alto Neuroscience, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alto Neuroscience, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Alto Neuroscience, Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 7th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of February 2025 Other Reports | ViewVerify |
Alto Stock media impact
Far too much social signal, news, headlines, and media speculation about Alto Neuroscience, that are available to investors today. That information is available publicly through Alto media outlets and privately through word of mouth or via Alto internal channels. However, regardless of the origin, that massive amount of Alto data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alto Neuroscience, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alto Neuroscience, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alto Neuroscience,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alto Neuroscience, alpha.
Alto Neuroscience, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Alto Neuroscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alto Neuroscience, Corporate Management
| Melissa Berman | Vice Accounting | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Jason Hoffman | Vice Resources | Profile | |
| Erin JD | General Officer | Profile |
Already Invested in Alto Neuroscience,?
The danger of trading Alto Neuroscience, is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alto Neuroscience, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alto Neuroscience,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alto Neuroscience, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alto Neuroscience, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alto Neuroscience,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alto Neuroscience, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alto Neuroscience, Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Alto Neuroscience,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.